4.6 Article

Early treatment of type II SMA slows rate of progression of scoliosis

Journal

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/jnnp-2023-332084

Keywords

SPINAL MUSCULAR ATROPHY; PAEDIATRIC NEUROLOGY; NEUROPSYCHIATRY

Ask authors/readers for more resources

This study aims to evaluate potential differences in scoliosis progression between treated and untreated type II spinal muscular atrophy (SMA) patients. The results indicate that pharmacological treatment, if initiated early, may slow down the progression of scoliosis in SMA patients.
Background Type II spinal muscular atrophy (SMA) often leads to scoliosis in up to 90% of cases. While pharmacological treatments have shown improvements in motor function, their impact on scoliosis progression remains unclear. This study aims to evaluate potential differences in scoliosis progression between treated and untreated SMA II patients. Methods Treatment effect on Cobb's angle annual changes and on reaching a 50 degrees Cobb angle was analysed in treated and untreated type II SMA patients with a minimum 1.5-year follow-up. A sliding cut-off approach identified the optimal treatment subpopulation based on age, Cobb angle and Hammersmith Functional Motor Scale Expanded at the initial visit. Mann-Whitney U-test assessed statistical significance. Results There were no significant differences in baseline characteristics between the untreated (n=46) and treated (n=39) populations. The mean Cobb angle variation did not significantly differ between the two groups (p=0.4). Optimal cut-off values for a better outcome were found to be having a Cobb angle <26 degrees or an age <4.5 years. When using optimal cut-off, the treated group showed a lower mean Cobb variation compared with the untreated group (5.61 (SD 4.72) degrees/year vs 10.05 (SD 6.38) degrees/year; p=0.01). Cox-regression analysis indicated a protective treatment effect in reaching a 50 degrees Cobb angle, significant in patients <4.5 years old (p=0.016). Conclusion This study highlights that pharmacological treatment, if initiated early, may slow down the progression of scoliosis in type II SMA patients. Larger studies are warranted to further investigate the effectiveness of individual pharmacological treatment on scoliosis progression in this patient population.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available